Browse the evidence

Tirzepatide reduced the risk of major adverse cardiovascular events (MACEs) (HR, 0.743; 95% CI, 0.673-0.821; p < 0.0001).

Tirzepatide may help reduce cardiovascular risks in obese patients.

Tirzepatide reduced the risk of major adverse kidney events (MAKEs) (HR, 0.375; 95% CI, 0.336-0.419; p < 0.0001).

Tirzepatide may be beneficial for kidney health in obese patients.

Resolution of steatohepatitis without worsening of fibrosis occurred in 62.9% of the patients in the semaglutide group compared to 34.3% in the placebo group.

Semaglutide may be an effective treatment option for improving liver histology in patients with MASH.

In the 15-mg tirzepatide group, 62% of participants achieved resolution of MASH without worsening of fibrosis compared to 10% in the placebo group (difference of 53 percentage points; P<0.001).

Tirzepatide may be an effective treatment option for patients with MASH and moderate to severe fibrosis.

GLP-1 RA use is associated with increased risk of gallbladder or biliary diseases for longer durations (RR, 1.40; 95% CI, 1.26-1.56) compared to shorter durations (RR, 0.79; 95% CI, 0.48-1.31).

Clinicians should monitor patients on GLP-1 RAs for gallbladder issues, especially with prolonged use.

High intake of carbohydrates with a high glycemic index is associated with greater insulin resistance compared to low-glycemic-index carbohydrates.

Practitioners should consider recommending low-glycemic-index carbohydrates to improve insulin sensitivity.

1-year reinitiation was lower for those without type 2 diabetes (36.3%) compared with those with type 2 diabetes (47.3%).

Practitioners should note that patients without type 2 diabetes may have lower rates of reinitiating GLP-1 RA therapy.

Women engaged in higher amounts of recent total physical activity (≥27 MET-h/wk) were at lower breast cancer risk (HR, 0.85; 95% CI, 0.78-0.93).

Encouraging higher levels of physical activity may help reduce breast cancer risk in postmenopausal women.

Brisk walking was associated with lower breast cancer risk (per 20 MET-h/wk: HR, 0.91; 95% CI, 0.84-0.98).

Encouraging brisk walking can be an effective strategy to lower breast cancer risk.

Weight loss achieved through GLP-1–based antiobesity medications affects weight regain, fat-free mass, and skeletal muscle mass in people with obesity.

Practitioners should consider the impact of GLP-1 medications on body composition when managing obesity.

Different diets may change hormonal secretion, gut-brain signaling, and influence hunger, satiety, and energy expenditure.

Dietary recommendations should consider the hormonal and signaling effects on appetite and energy balance.

Wegovy rose from 989 in 2021 to 2992 in 2022.

The increase in Wegovy usage suggests a rising interest in GLP-1 receptor agonists for weight loss.

The monthly growth rates were 83.9% for Ozempic and 119.2% for Wegovy.

High monthly growth rates indicate a significant trend towards the use of GLP-1 receptor agonists for weight loss.

Liraglutide, 3.0 mg, is safe with no serious adverse events or treatment-related deaths reported.

Liraglutide can be considered a safe option for weight management in the studied population.

The infusion of amino acids resulted in an additional reduction in endogenous Ra and a blunting of NORd reduction at each dose of insulin.

Amino acids can enhance insulin's ability to suppress protein breakdown.

Insulin secretion was negatively associated with the rate of weight gain.

Lower insulin secretion may indicate a higher risk of weight gain, which can inform dietary and lifestyle interventions.

Resistance training (RT) induces significant endogenous hormonal elevations.

Incorporating resistance training can enhance hormonal levels beneficial for muscle growth.

Bariatric surgery and GLP-1 receptor agonists have similar effects on glycemic control.

Both treatment options can be considered for glycemic control in obese patients.

HGF protein significantly increases in serum from baseline to 4 hours post-exercise.

Monitoring HGF levels may provide insights into muscle recovery following exercise.

Tirzepatide treatment was associated with lower hazards of all-cause mortality compared to GLP-1 RA (adjusted hazard ratio [AHR], 0.58; 95% CI, 0.45-0.75).

Practitioners may consider tirzepatide as a safer option for reducing mortality risk in patients with type 2 diabetes.

Tirzepatide treatment was associated with lower hazards of major adverse cardiovascular events (MACEs) compared to GLP-1 RA (AHR, 0.80; 95% CI, 0.71-0.91).

Tirzepatide may be a preferable treatment option for reducing cardiovascular risks in patients with type 2 diabetes.

Twins on the vegan diet had a significant mean decrease in fasting insulin level of -2.9 μIU/mL after 8 weeks.

Clinicians may consider a vegan diet to improve insulin sensitivity in patients.

PTH decreased in the high protein and high dairy and adequate protein and medium dairy groups compared to the low dairy group.

Reducing dairy intake may negatively impact PTH levels, which are important for bone health.

Low glycemic index diets may be useful in the prevention and treatment of obesity and related complications.

Practitioners may consider recommending low glycemic index diets for weight management.